Nextech Crossover I GP S.a r.l. 13D and 13G filings for Mersana Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-12-26 4:29 pm Unchanged |
2024-12-20 | 13G | Mersana Therapeutics, Inc. MRSN |
Nextech Crossover I GP S.a r.l. | 12,067,246 10.400% |
0 (Unchanged) |
Filing |
| 2024-11-14 5:45 pm Purchase |
2024-09-30 | 13G | Mersana Therapeutics, Inc. MRSN |
Nextech Crossover I GP S.a r.l. | 12,067,246 9.800% |
5,818,403 (+93.11%) |
Filing |
| 2024-05-17 08:26 am Purchase |
2024-05-14 | 13G | Mersana Therapeutics, Inc. MRSN |
Nextech Crossover I GP S.a r.l. | 6,248,843 5.100% |
6,248,843 (New Position) |
Filing |